shot-button
Subscription Subscription
Home > Mumbai > Mumbai News > Article > Nair KEM start giving 2nd dose of COVID 19 vaccine in Oxford trial

Nair, KEM start giving 2nd dose of COVID-19 vaccine in Oxford trial

Updated on: 03 November,2020 07:09 AM IST  |  Mumbai
Arita Sarkar |

Officials said there have been no major side-effects after first round of administration, and a few who exhibited mild effects like fever were treated with paracetamol

Nair, KEM start giving 2nd dose of COVID-19 vaccine in Oxford trial

Nair hospital also has 48 more participants in the trial now. Representation pic

Both KEM Hospital and Nair Hospital, centres for the ongoing Oxford vaccine trial for COVID-19, have finished administering the first dose to participants and have started with the second round. While both centres had asked for an additional target, Nair received the approval of the Indian Council of Medical Research (ICMR) and added 48 participants.


Late last month, a representation was sent to ICMR of adding more participants to the existing quota of 100 candidates for each hospital.


Representation pic
Representation pic


Dr Ramesh Bharmal, dean of Nair hospital, said, "We had asked for permission from the ICMR and since AIIMS has fewer candidates, we were allowed to add more. We have given the first dose to all candidates and the second round started last week," he said.

Dr Bharmal added that so far around 12-15 candidates have received the second dose and no one has reported side effects.

The BCG vaccine trial is being done on adults to fight COVID-19. Representation pic
The BCG vaccine trial is being done on adults to fight COVID-19. Representation pic

"A few of the candidates reported mild effects like fever and body ache that can be treated with paracetamol. No one has any major side effects and the trial is going well so far," he said.

Additional Municipal Commissioner Suresh Kakani said that KEM Hospital has maintained the original target of 100 candidates and has started giving the second dose.

KEM Hospital. File pic
KEM Hospital. File pic

As per the protocol, the same pool of candidates will be involved in the Phase II (two doses) and phase III (single dose) of the trial and will be monitored for six months. The second dose in Phase II is given 29 days after the first one and three months later, the third dose is given.

The BCG trial

Apart from the Oxford trial, KEM Hospital is also managing the BCG vaccine trial for COVID-19 and ICMR has increased the sample size for the trial from 1,450 to 1,555 candidates along with 778 participants as part of the control group.

Dr Rujuta Hadaye from the Department of Community Medicine who is heading the trial said, "Since the sero positivity rate was high, ICMR increased the target and added centres in September. A deadline for October 30 was given. However, we are still working and will finish by the end of this month."

Dr Hadaye said that they have screened more than 275 people till date and have given the vaccine dose to nearly 100 people. To speed things up, Dr Hadaye said that ICMR added five centres to the existing six, which reduced the target for each of them.

3
Total no. of phases in the Oxford vaccine trial

12-15
Candidates at Nair who got second dose of vaccine

148
Total no. of participants in Nair hospital trial

02
No. of doses in Phase II of the Oxford vaccine trial

1,555
No. of target participants in the BCG vaccine trial

Keep scrolling to read more news

Catch up on all the latest Mumbai news, crime news, current affairs, and a complete guide from food to things to do and events across Mumbai. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK